Sapient Capital LLC Reduces Stock Holdings in Intensity Therapeutics Inc. $INTS

Sapient Capital LLC lowered its position in Intensity Therapeutics Inc. (NASDAQ:INTS) by 33.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 650,151 shares of the company’s stock after selling 326,646 shares during the quarter. Sapient Capital LLC’s holdings in Intensity Therapeutics were worth $244,000 at the end of the most recent reporting period.

Separately, Mesirow Financial Investment Management Inc. boosted its stake in Intensity Therapeutics by 81.8% during the third quarter. Mesirow Financial Investment Management Inc. now owns 200,000 shares of the company’s stock worth $49,000 after buying an additional 90,000 shares during the period. 3.74% of the stock is currently owned by institutional investors and hedge funds.

Intensity Therapeutics Stock Performance

Shares of INTS opened at $4.59 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.01. The firm has a market cap of $12.39 million, a PE ratio of -0.80 and a beta of 2.94. The company’s 50 day simple moving average is $5.67 and its 200-day simple moving average is $8.63. Intensity Therapeutics Inc. has a 12-month low of $4.50 and a 12-month high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.12. As a group, equities analysts predict that Intensity Therapeutics Inc. will post -2.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on INTS shares. Weiss Ratings lowered shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, April 24th. Freedom Capital raised shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th. Finally, Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.50.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.